Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nautilus Neurosciences, a neurology-focused specialty pharmaceutical company, has received US patent entitled, Diclofenac formulations and methods of use.
Subscribe to our email newsletter
This patent relates to methods and formulations for treating migraine, symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
The patent provides additional protection for Cambia, Nautilus’ marketed product for the treatment of migraine through June 2026.
This patent was licensed to Nautilus for Cambia in the North American markets by the Swiss company APR Applied Pharma Research, and is now listed in the FDA’s Orange Book, the company said.